Search Results
Results found for "GPCR autoantibodies"
- Crinetics Pharmaceuticals Announces Pricing Of Underwritten Common Stock Offering
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares reported its FY2021 financial result and provided an update on operational activities
February 2022 Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Pharmaceuticals Expands Executive Team With Appointment Of James Hassard As Chief ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Sosei Heptares Enters Antibody Discovery Agreement with Twist Bioscience to Discover and Develop ...
Discovery Agreement with Twist Bioscience to Discover and Develop Novel Therapeutic Antibodies against GPCR world-leading StaR® (stabilized receptor) platform to generate novel antibody leads to disease-relevant GPCR Cambridge, UK, 16 December 2021 – Sosei Group Corporation (“the Company”; TSE: 4565), the world leader in GPCR-focused announced a strategic collaboration to discover therapeutic antibodies against G protein-coupled receptors (GPCR Read more at the source #DrGPCR #GPCR #IndustryNews
- Inversago Pharma Announces Dosing of First Participant with Metabolic Syndrome in Phase 1B ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Orion Announces The Rapid Lead Optimization Of Ob-004 - A Ccr2 Antagonist
Biotechnology, a clinical stage company unlocking the therapeutic potential of G Protein-Coupled Receptors (GPCRs OB-004 is a GPCR targeted protein analog of CCL2 that targets the CCR2 receptor. Read more at the source #DrGPCR #GPCR #IndustryNews
- VIB spin-off Confo Therapeutics Enters Collaborative Agreement with Regeneron
December 2021 "30/11/2021 Confo will work together with Regeneron to apply its GPCR drug discovery platform technology platform, which uses conformationally selective VHH antibodies – ConfoBodies® – to stabilize GPCRs enabling the discovery of novel therapeutic antibody drug candidates. " Read more at the source #DrGPCR #GPCR
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
GPCRs couple, decouple, isomerize, deplete tracers, and shift apparent affinity depending on stoichiometry ll gain: Why saturation and displacement assays fail when protein stoichiometry shifts How two-stage GPCR Complex Two-Stage Biology Behind Orthosteric Binding GPCR pharmacology rarely follows the neat Langmuir Clues that point to true multiple-site binding rather than two-stage GPCR biology: Disrupting G protein leaders who need credible guidance fast, the Corner brings clarity to the complexities shaping modern GPCR
- ShouTi Pharma has a brand new website
Read more at the source #DrGPCR #GPCR #IndustryNews
- Learn more about Neurocrine Biosciences with their new video
Read more at the source #DrGPCR #GPCR #IndustryNews
- Trevena Announce Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Finding needles in haystacks: Omass unveils pipeline aimed at tough-to-drug targets
The targets, including G protein-coupled receptors (GPCRs), intracellular protein complexes and solute Read more at the source #DrGPCR #GPCR #IndustryNews
- Newly launched antibody libraries put hard-to-drug targets within reach
To target hard-to-drug targets like G protein-coupled receptors (GPCRs), more libraries, including better Read more at the source #DrGPCR #GPCR #IndustryNews
- Dr. Alexander S. Hauser receives the Bachem award for peptide science
November 2021 Read more at the source #DrGPCR #GPCR #IndustryNews
- Dr. Thomas P. Sakmar receives an honorary doctorate from Karolinska Institute
Read more at the source #DrGPCR #GPCR #IndustryNews
- Perkins’ Head of Molecular Endocrinology and Pharmacology, Professor Kevin Pfleger, was appointed...
Read more at the source #DrGPCR #GPCR #IndustryNews
- First in Human: Early-stage COVID therapies hold promise against omicron variant
Read more at the source #DrGPCR #GPCR #IndustryNews
- Why “Displacement” Misleads You: Allosteric Binding Demystified
If your project involves GPCRs , functional selectivity , or non-traditional ligands , this session is Subscribe to The Kenakin Brief today ➤ #AllostericPharmacology #GPCR #BindingVsFunction #ReceptorPharmacology
- Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team
Read more at the source #DrGPCR #GPCR #IndustryNews
- Search for safer pain relief advances with new engineered compounds
Read more at the source #DrGPCR #GPCR #IndustryNews
- Crinetics Pharmaceuticals announced the formation of an independently operated new company...
Read more at the source #DrGPCR #GPCR #IndustryNews
- California gold rush for Sosei Heptares
Read more at the source #DrGPCR #GPCR #IndustryNews
- Dr. Kevin Pfleger and Dr. Elizabeth Johnstone were awarded one of the 2022 Diabetes Research...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...
potential global development of ADX71149 for the treatment of epilepsy. " Read more at the source #DrGPCR #GPCR
- Novel interaction between neurotrophic factor-α1/carboxypeptidase E and serotonin receptor, 5-HTR1E,
"Protecting neurons from death during oxidative and neuroexcitotoxic stress is key for preventing cognitive dysfunction. We uncovered a novel neuroprotective mechanism involving interaction between neurotrophic factor-α1 (NF-α1/carboxypeptidase E, CPE) and human 5-HTR1E, a G protein-coupled serotonin receptor with no previously known neurological function. Co-immunoprecipitation and pull-down assays confirmed interaction between NFα1/CPE and 5-HTR1E and 125I NF-α1/CPE-binding studies demonstrated saturable, high-affinity binding to 5-HTR1E in stably transfected HEK293 cells (Kd = 13.82 nM). Treatment of 5-HTR1E stable cells with NF-α1/CPE increased pERK 1/2 and pCREB levels which prevented a decrease in pro-survival protein, BCL2, during H2O2-induced oxidative stress. Cell survival assay in β-arrestin Knockout HEK293 cells showed that the NF-α1/CPE-5-HTR1E-mediated protection against oxidative stress was β-arrestin-dependent. Molecular dynamics studies revealed that NF-α1/CPE interacts with 5-HTR1E via 3 salt bridges, stabilized by several hydrogen bonds, independent of the serotonin pocket. Furthermore, after phosphorylating the C-terminal tail and intracellular loop 3 (ICL3) of NF-α1/CPE-5-HTR1E, it recruited β-arrestin1 by forming numerous salt bridges and hydrogen bonds to ICL2 and ICL3, leading to activation of β-arrestin1. Immunofluorescence studies showed 5-HTR1E and NF-α1/CPE are highly expressed and co-localized on cell surface of human hippocampal neurons. Importantly, knock-down of 5-HTR1E in human primary neurons diminished the NF-α1/CPE-mediated protection of these neurons against oxidative stress and glutamate neurotoxicity-induced cell death. Thus, NF-α1/CPE uniquely interacts with serotonin receptor 5-HTR1E to activate the β-arrestin/ERK/CREB/BCL2 pathway to mediate stress-induced neuroprotection." Read full article
- Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital ...
Read more at the source #DrGPCR #GPCR #IndustryNews
- How Fast Does a Drug Work?
s Corner ______ #DrugDiscovery #Pharmacology #DrugKinetics #PipelineEfficiency #PharmaInnovation #GPCR
